Claims for Patent: 10,526,381

Summary for Patent: 10,526,381

Title:	Multivalent and monovalent multispecific complexes and their uses
Abstract:	Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.
Inventor(s):	Roschke; Viktor (Bethesda, MD), Lafleur; David (Washington, DC), Hilbert; David M. (Bethesda, MD), Kiener; Peter (Potomac, MD)
Assignee:	Zygenia, Inc. (Washington, DC)
Application Number:	15/458,079
Patent Claims:	1. A complex comprising an antibody linked to a modular recognition domain (MRD) capable of binding angiopoietin-2 (ANG-2), wherein the antibody binds to tumor necrosis factor alpha (TNF), and wherein the MRD comprises amino acid sequence DCAVYPNPPWCYKMEFGK (SEQ ID NO: 16). 2. The complex of claim 1, wherein the antibody is selected from the group consisting of: adalimumab, golimumab, and infliximab. 3. A pharmaceutical composition comprising the complex of claim 1 and a pharmaceutically acceptable carrier. 4. A method for inhibiting angiogenesis in a patient comprising administering to said patient a therapeutically effective amount of the complex of claim 1. 5. The complex of claim 1, wherein the MRD is linked to the antibody directly. 6. The complex of claim 1, wherein the MRD is linked to the antibody through a linker. 7. A complex comprising an antibody linked to an MRD capable of binding angiopoietin-2 (ANG-2), wherein the antibody is adalimumab and the MRD comprises the amino acid sequence DCAVYPNPPWCYKMEFGK (SEQ ID NO: 16). 8. The complex of claim 7, wherein the MRD is linked to the antibody directly. 9. The complex of claim 7, wherein the MRD is linked to the antibody through a linker. 10. A pharmaceutical composition comprising the complex of claim 7 and a pharmaceutically acceptable carrier. 11. A complex comprising an antibody linked to an MRD capable of binding angiopoietin-2 (ANG-2), wherein the antibody is golimumab and the MRD comprises the amino acid sequence DCAVYPNPPWCYKMEFGK (SEQ ID NO: 16). 12. The complex of claim 11, wherein the MRD is linked to the antibody through a linker. 13. The complex of claim 11, wherein the MRD is linked to the antibody directly. 14. A pharmaceutical composition comprising the complex of claim 11 and a pharmaceutically acceptable carrier. 15. A complex comprising an antibody linked to an MRD capable of binding angiopoietin-2 (ANG-2), wherein the antibody is infliximab and the MRD comprises the amino acid sequence DCAVYPNPPWCYKMEFGK (SEQ ID NO: 16). 16. The complex of claim 15, wherein the MRD is linked to the antibody through a linker. 17. The complex of claim 15, wherein the MRD is linked to the antibody directly. 18. A pharmaceutical composition comprising the complex of claim 15 and a pharmaceutically acceptable carrier. 19. A peptide capable of binding angiopoietin-2 (ANG-2), wherein the peptide comprises the amino acid sequence of SEQ ID NO: 16. 20. A fusion peptide comprising the peptide of claim 19 and a heterologous peptide.

Details for Patent 10,526,381

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2040-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2040-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2040-01-24